Welcome to BIOiSIMTM │ Drug Discovery & Development Technology
Introducing BIOiSIM®
BIOiSIM® is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease.
“At a time when numerous smaller organizations are over-selling their AI efforts as cure-alls, I found VSL's down-to-earth but competent and insightful approach very refreshing...I would not hesitate to recommend them for organizations looking for professional and knowledgeable external ML solutions.”
— Associate Director at Genentech
BIOiSIM Offerings
Services
We provide technology enabled services to address your translational challenges guided by our unique Translational Index® capability. Engage with our professionals to quickly impact your program's journey toward more successful clinical trial outcomes.
Speak with a Sales representative >
Partnership
We partner with organizations to co-develop new drugs using our platform to predict translation and reduce R&D waste. These deep collaborations significantly de-risk the selection of new candidates and shorten development time.
Contact our Corporate Development team >
Our Proven Platform
SCALABLE MODELS
Our models are built on data from thousands of compounds across 7 species, leading to a robustness rarely seen in the industry.
Early Insights
The BIOiSIM® platform can be used before preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.
Artificial Intelligence and Mechanistic Models
VeriSIM Life has shown that the best models are developed by using a hybrid mixed-model approach to drug insights, leading to greater accuracy and scalability.
Great Translatability
With a focus on human outcomes, the platform has at its core a translatability engine that transforms insights across species.
Continuous Development
The team employs a continuous improvement process to iterate on data stability, improve models, and provide an always up-to-date software service.
Fast Model Development
The flexibility of the platform and generations of customer-ready tools allows for the development of custom models and validations within weeks.
BIOiSIM® enables your team with a novel platform that focuses your development efforts on the drug compounds that are more likely to deliver on the anticipated value for the treatment or cure of a specific disease.
Current
With VeriSIM
~10 years
<5 years
Additional Benefits
Specific to Desired Output
With our framework, we can quickly develop custom, specific models.
- Trained on diverse data across various animal and human species
- Validated with both FDA and proprietary compounds.
- Expanding feature set: we are always adding new functionality and expanding the domain of applicability.
- Multiple routes of administration: we simulate various routes of administrations such as IV, oral, and transdermal and others.
- Rapid result generation: our platform is cloud-based and generates predictions in seconds.
- Self-learning: our model extracts conclusions from complex and convoluted data.
Give your development pipeline an edge
Speak to one of our experts today
Benefits
Meaningful outcomes powered by BIOiSIM
VeriSIM Life’s first-in-class, drug decision engine, BIOiSIM, offers actionable insights of unprecedented value to the drug development industry.
Increase clinical success: avoid the design and pursuit of dead end candidates. Guide decision-making with BIOiSIM’s Translational Index®, which advances only the most promising drug candidates through R&D to investigational new drug (IND) application.
Earlier insights: faster drug R&D. BIOiSIM's integrated drug design and development platform identifies new drug candidates with clinical success designed in from day one, while flexibly adapting to address a range of translation challenges – reducing the time it takes to get to IND status by an average of 2.5 years.
Reduce waste, lower costs: with greater accuracy and scalability, BIOiSIM’s robust, hybrid AI/ML engine reduces the need for unnecessary in vivo experimentation, representing a $3 million cost savings when compared to conventional testing.
The BIOiSIM Advantage
Predictive insights and groundbreaking intelligence for drug R&D
1
- Trillion
Novel drug discovery search space
1.5
Million
Real validation simulations and counting 400
Billion
Simulation scenario capacity
↑
1
% More Accurate
Than other non-AI enhanced models ↓
2.5
Years
Get to IND status 2.5 years faster
BIOiSIM® Platform
Features
Breakthrough AI to advance & de-risk R&D translation
The BIOiSIM platform combines a vast chemical search space, thousands of validation data sets, multi-compartmental models, machine learning, deep learning and large language models to achieve next-level chemical and biological relevance for drug design and translation agnostic to indication or modality.
.png)
AtlasGEN™ Novel Drug Designer
Synergistically marries powerful novel drug design chemistry with biological validation to discover clinically successful novel therapies.
Translational Index®
VeriSIM Life’s Translational Index informs preclinical research and development decisions, akin to the role a FICO credit score plays in evaluating consumer creditworthiness. The Translational Index score is a multi-metric synthesis of a compound’s likely therapeutic effect, including its safety and efficacy.
Hybrid mechanistic model & artificial intelligence engine
Integrates the inferential and extractive strengths of machine learning techniques with deterministic, mechanistic bio- and physiological models to yield more informed and predictive results than empirical science alone.
Minimalistic generalization
Provides predictions without the need for large empirical datasets that are translatable across different species, routes of administration and therapeutic areas, greatly reducing overfit and specialization.
Continuous benchmarking & learning
Undergoes frequent algorithm checks to reinforce learning, while tracking changes to predictiveness baselines; ongoing training and validation simulations allow for continuous learning and accuracy.
Accessible synthesis & scalability
Drives high-value decisions through the platform’s cloud-based computational system – fully scalable, optimized for high-speed processing, and supporting 800 billion total potential simulation scenarios.
Cross-disciplinary, science & data backbone
Preserves scientific context and maintains structural integrity, boasting a growing, proprietary, structure-related data lake for >3M+ compounds, >5000+ unique animal and human validation datasets, physiological parameters of 196+ different subject populations. Uniquely augmented with relevant synthetic data.
Partnerships and Services
Unified technology, accessible in a range of ways
New drug partnerships
We partner with biotech and pharma clients to identify successful novel candidates for difficult targets. Collaborate with a discovery enabler with the unique ability to merge biological relevance with target engagement chemistry, designing in clinical success from day one.
Platform-enabled services
We tailor our BIOiSIM-enabled services and Translational Index technology to address your organization’s specific translational challenges and help you achieve more successful clinical trial outcomes.
Translational Index Scorecard
With compound structure data only, BIOiSIM can predict multiple aspects of translatability across multiple animal species and for humans. See how your candidate scores!
Collaborative asset development
We partner with organizations to co-develop new drugs using the BIOiSIM platform to more accurately predict translatability and reduce R&D waste. These deep collaborations significantly de-risk the selection of new candidates and shorten development time.
Empowering our partners to bring better drugs to market, faster.
Our mission at Debiopharm is to develop tomorrow’s standard of care for cancer and improve patient quality of life. Accelerating the translation of our research to clinical success is a priority, and our work with VeriSIM Life is focused on this critical objective. With insights from the BIOiSIM platform, we believe our innovative therapies will rapidly move closer to addressing the unmet needs of cancer patients worldwide.
Dr. Valerie Nicolas, Deputy to the Head of Translational Medicine at Debiopharm